Table 2 The association of renal diagnosis to observed and expected cancer incidence (%/year) grouped according to time interval relative to biopsy date

Minimal change

Observed

0.19

0.24

0.82

1.40

2.44

1.39

0.64

0.72

0.73

Expected

0.15

0.23

0.31

0.41

0.59

0.64

0.71

0.84

0.45

Risk ratio

1.2 (0.3–3.2)

1.0 (0.1–3.8)

2.6 (1.1–5.4) ^a

3.4 (1.2–7.4) ^b

4.1 (2.0–7.6) ^c

2.2 (1.0–4.0) ^a

0.9 (0.2–2.3)

0.9 (0.4–1.6)

1.6 (1.2–2.1) ^c

Endocapillary

Observed

0.15

0.36

1.09

1.46

3.32

0.50

1.51

0.29

0.72

Expected

0.14

0.21

0.29

0.39

0.58

0.63

0.71

0.84

0.42

Risk ratio

1.1 (0–6.1)

1.8 (0–9.9)

3.8 (0.8–11.2) ^a

3.7 (0.4–13.4)

5.8 (1.6–14.7) ^b

0.8 (0–4.4)

2.1 (0.3–7.7)

0.3 (0–1.9)

1.7 (1.0–2.9) ^a

Focal segmental glomerulosclerosis

Observed

0.35

0.74

0.86

1.72

2.08

1.05

0.92

2.10

0.96

Expected

0.20

0.32

0.44

0.57

0.81

0.89

1.00

1.19

0.57

Risk ratio

1.8 (0.7–3.6)

2.3 (0.9–5.1) ^a

1.9 (0.8–4.0)

3.0 (1.2–6.2) ^a

2.5 (1.1–5.0) ^a

1.2 (0.5–2.4)

0.9 (0.3–2.4)

1.8 (0.9–3.0) ^p = 0.06

1.7 (1.3–2.2) ^c

Mesangio- proliferative

Observed

0.17

0.38

0.34

0.76

1.05

0.83

0.97

1.14

0.58

Expected

0.12

0.19

0.26

0.36

0.50

0.56

0.63

0.77

0.38

Risk ratio

1.4 (0.7–2.6)

2.0 (0.9–3.9) ^a

1.3 (0.6–2.5)

2.1 (1.0–4.1) ^a

2.1 (1.0–3.8) ^a

1.5 (0.8–2.5)

1.5 (0.9–2.5)

1.5 (1.0–2.1) ^a

1.5 (1.2–1.8) ^c

Membranous

Observed

0.30

0.55

0.74

0.94

3.90

1.77

0.93

2.39

1.10

Expected

0.22

0.33

0.47

0.62

0.91

0.99

1.10

1.30

0,65

Risk ratio

1.4 (0.7–2.5)

1.6 (0.7–3.2)

1.6 (0.8–2.9)

1.5 (0.6–3.1)

4.3 (2.8–6.3) ^c

1.8 (1.1–2.8) ^a

0.8 (0.4–1.6)

1.8 (1.3–2.6) ^c

1.7 (1.4–2.0) ^c

Membrano- proliferative

Observed

0.48

0.34

0.68

3.04

3.81

2.24

1.45

1.05

1.18

Expected

0.20

0.30

0.42

0.54

0.78

0.85

0.94

1.10

0.55

Risk ratio

2.4 (1.0–4.9) ^a

1.1 (0.1–4.0)

1.6 (0.4–4.1)

5.6 (2.6–10.6) ^c

4.9 (2.3–9.0) ^c

2.6 (1.2–5.0) ^b

1.5 (0.4–4.0)

1.0 0.4–2.0)

2.2 (1.6–2.8) ^c

Proliferative

Observed

0.53

0

0.88

1.78

1.92

0

0

2.95

0.87

Expected

0.14

0.22

0.31

0.41

0.60

0.66

0.74

0.88

0.43

Risk ratio

3.7 (0.8–10.8) ^a

0 (0–7.6)

2.9 (0.3–10.4)

4.3 (0.5–15.5)

3.2 (0.4–11.5)

0 (0–3.2)

0 (0–3.5)

3.4 (1.1–7.8) ^c

2.0 (1.1–3.4) ^a

Focal segmental proliferative

Observed

0.16

0.20

0.49

0.79

1.14

1.29

1.50

1.76

0.74

Expected

0.17

0.26

0.36

0.49

0.71

0.78

0.87

1.02

0.52

Risk ratio

0.9 (0.3–2.4)

0.8 (0.1–2.8)

1.4 (0.5–3.2)

1.6 (0.4–4.2)

1.6 (0.5–3.7)

1.7 (0.8–3.0)

1.7 (0.8–3.2)

1.7 (1.1–2.6) ^a

1.4 (1.1–1.8) ^b

Focal

Observed

0

1.03

0.35

1.37

1.67

0.66

2.48

0.95

0.70

Expected

0.29

0.44

0.61

0.78

1.14

1.23

1.34

1.55

0.75

Risk ratio

0 (0–1.8)

2.3 (0.5–6.9)

0.6 (0–3.3)

1.8 (0.2–6.4)

1.5 (0.2–5.3)

0.5 (0–3.0)

1.9 (0.4–5.4)

0.6 (0.1–1.8)

0.9 (0.5–1.6)

Crescentic

Observed

0.23

0.49

0.49

1.31

1.00

1.88

2.49

2.28

0.91

Expected

0.30

0.46

0.64

0.84

1.25

1.34

1.46

1.67

0.79

Risk ratio

0.8 (0.3–1.6)

1.1 (0.4–2.3)

0.8 (0.3–1.9)

1.6 (0.7–3.1)

0.8 (0.3–1.9)

1.4 (0.8–2.4)

1.7 (0.9–2.9)

1.4 (0.8–2.1)

1.2 (0.9–1.4)

Unclassified

Observed

0.58

1.09

1.18

7.43

6.71

2.41

1.44

2.10

1.94

Expected

0.28

0.43

0.59

0.77

1.14

1.22

1.33

1.52

0.74

Risk ratio

2.1 (1.2–3.3) ^a

2.5 (1.3–4.4) ^b

2.0 (1.1–3.4) ^a

9.7 (6.9–13.1) ^c

5,9 (4.0–8.3) ^c

2,0 (1.2–3.1) ^b

1.1 (0.4–2.2)

1.4 (0.8–2.3)

2.6 (2.2–3.1) ^c

Anti-GBM GN

Observed

0.00

0.54

0.00

0.00

1.22

3.11

0.00

2.93

0.6

Expected

0.31

0.46

0.62

0.80

1.20

1.26

1.34

1.49

0.7

Risk ratio

0 (0–2.6)

1.2 (0–6.6)

0 (0–3.3)

0 (0–5.1)

1.0 (0–5.7)

2.5 (0.5–7.2)

0 (0–2.8)

2.0 (0.4–5.8)

0.8 (0.4–1.6)

ANCA-associated vasculitis

Observed

0.50

0.54

1.08

1.80

2.96

1.90

2.43

2.48

1.37

Expected

0.29

0.45

0.62

0.84

1.27

1.36

1.48

1.69

0.84

Risk ratio

1.72 (0.7–3.5)

1.2 (0.2–3.5)

1.7 (0.6–3.8)

2.1 (0.7–5.0)

2.3 (0.9–4.8)

1.4 (0.6–2.9)

1.6 (0.7–3.1)

1.5 (0.8–2.5)

1.6 (1.2–2.1) ^c

Lupus nephritis unspecified

Observed

0

0

0.51

0

1.14

1.71

2.40

0.75

0.60

Expected

0.10

0.15

0.21

0.28

0.40

0.44

0.49

0.59

0.31

Risk ratio

0 (0–7.9)

0 (0–12.7)

2.4 (0.1–13.6)

0 (0–13.3)

2.9 (0.1–15.9)

3.9 (0.5–14.0)

4.9 (0.6–17.6)

1.3 (0.3–3.7)

1.9 (0.9–3.7)

Lupus nephritis all

Observed

0.10

0.24

0.24

0.24

0.78

0.83

0.56

0.89

0.42

Expected

0.09

0.14

0.19

0.25

0.34

0.38

0.43

0.52

0.26

Risk ratio

1.1 (0.1–3.9)

1.7 (0.2–6.3)

1.2 (0.1–4.4)

0.9 (0–5.3)

2.3 (0.5–6.8)

2.2 (0.7–5.2)

1.3 (0.2–4.7)

1.7 (0.9–3.0)

1.6 (1.1–2.3) ^a

Any

Observed

0.28

0.49

0.66

1.83

2.51

1.48

1.34

1.71

0.96

Expected

0.20

0.31

0.43

0.57

0.83

0.90

1.00

1.17

0.58

Risk ratio

1.4 (1.1–1.7) ^b

1.6 (1.2–2.1) ^b

1.5 (1.2–1.9) ^c

3.2 (2.6–3.9) ^c

3.0 (2.5–3.6) ^c

1.6 (1.4–2.0) ^c

1.3 (1.1–1.7) ^a

1.5 (1.3–1.7) ^c

1.7 (1.5–1.8) ^c